Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Before Amgen, the largest biotech company in the world, acquired Micromet in one of the splashiest biotech deals in Europe, Micromet licensed its BiTE technology to Boehringer Ingelheim. Amgen is now taking over the development of BI’s Multiple Myeloma therapy to consolidate its hold on the bispecific antibodies. Boehringer Ingelheim has handed Amgen the keys to its Bispecific T cell […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Could Artificial Enzymes be the Future of Synthetic Chemistry?

As synthetic organic chemistry struggles to reinvent itself, the field is shifting its focus to emulating and engineering enzymes. A team of researchers in Basel has developed an artificial metalloenzyme with unique functionality that can be activated in a cell. Since the first example was published in 2015, artificial enzymes have been a hot topic […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 3 Sep 2016

Mouths & their Microbiomes Grow in this London Bioart Exhibit

Anna Dumitriu’s microbial art is at once revolting and captivating. She is showcasing her latest collaborative work on mouth bacteria at the Science Gallery London. Anna Dumitriu is a UK-based bioartist fascinated by the human microbiome: she creates art to express our relationships with the communities we host. We checked in on her earlier this year […]

September 3, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel). City: Vienna, Austria Founded: 2009 Employees: 4 Financial Data: €10M Total Raised (as of 12/2015) CEO: Erich Tauber Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop […]

September 2, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 2 Sep 2016

This €18M Joint Venture could Scale Up Bioplastic Film Production

Roughly 300 million tons of plastic are produced globally every year, but only 700 thousand tons are bio-based and biodegradable. Carbios’s new Joint Venture aims to dramatically grow this market. Carbios has announced the formation of CARBIOLICE, a new French joint venture shared between it, Limagrain Céréales Ingrédients (a heavyweight in the field of mulching films) […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Sep 2016

Infographic: How Cancer Starts & How It Chooses Organs

Here’s a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer. This information would help to explain the greater vulnerability of certain organs to tumors compared to others. The team, headed by Richard James Gilbertson, demonstrated that while cells may start with equal carcinogenic risk, tumor […]

September 1, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 1 Sep 2016

GSK is Advancing a Revolutionary Dual HIV Therapy

Gilead has long been the leader in HIV treatments, but GlaxoSmithKline’s CEO revealed to the WSJ that the company has been investing in the field. It could give Gilead a run for its money with dolutegravir, a new integrase inhibitor so powerful it may knock the standard down from triple to dual therapy. Since the […]

September 1, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in the Munich area, has taken home another trophy from the biosimilar battleground by scoring a second FDA approval for its copycat, Erelzi (etanercept-szzs). This drug mimics Enbrel, a €4.5B franchise managed by Amgen in the US that treats rheumatoid arthritis as well […]

August 31, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Evelyn Warner

About

Articles by Evelyn Warner

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Could Artificial Enzymes be the Future of Synthetic Chemistry?

Mouths & their Microbiomes Grow in this London Bioart Exhibit

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

This €18M Joint Venture could Scale Up Bioplastic Film Production

Infographic: How Cancer Starts & How It Chooses Organs

GSK is Advancing a Revolutionary Dual HIV Therapy

Novartis’ second FDA Biosimilar Approval could unlock Billions

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

Subscribe to our newsletter to get the latest biotech news!